



Third Quarter 2026

Financial and operating results for the period
ended September 30, 2026

October 29, 2026

Unless otherwise specified, comparisons in this presentation
are between 3Q25 and 3Q26.



IMPORTANT LEGAL INFORMATION

Forward-Looking Statements

Certain statements made in this presentation should be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These include statements about future results of operations and capital plans. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ, including those included in our press release issued on October 29, 2026, our Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. We assume no obligation to update this presentation, which speaks as of today's date.

Non-GAAP Measures

This presentation contains financial measures that differ from the comparable measures under Generally Accepted Accounting Principles (GAAP). Reconciliations between those non-GAAP measures and the comparable GAAP measures are included in the Appendix, or on the page such measure is presented.

While management believes the measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered substitutes for the most directly comparable GAAP measures.

Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors – Financials – SEC Filings" section of CNO's website, CNOinc.com.


OUR PURPOSE

We secure the future of middle-income America.



OUR MISSION

We secure the future of middle-income America by providing insurance and financial services that help protect their health, income and retirement needs, while building enduring value for all our stakeholders.



QUARTER IN REVIEW

Strong results continue; Raising full-year operating EPS guidance

Operational Highlights

- 17th consecutive quarter of sales growth
 - Sales growth in most product categories
 - Career field agents delivered growth in every major product line across both Divisions
 - Broad-based momentum across asset accumulation products
- 15th consecutive quarter of growth in producing agent count (PAC)
- Durable competitive moat generating consistent and repeatable sales growth

Financial Highlights

- Operating earnings per share (EPS)¹ up 47%; Year-to-date up 43%
 - Sales momentum driving profitable growth
 - Continued strong underwriting and net investment income (NII) results
 - Operating return on equity (ROE) of 14.1%, excluding significant items¹
- In October, executed 3rd reinsurance transaction with Bermuda affiliate
- Robust total capital position
- Returned \$77 million to shareholders
- Book value per diluted share excluding AOCI¹ of \$41.29, up 8%

¹ A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure.

GROWTH SCORECARD

Sustained and repeatable growth

		2025			2026			Change vs 3Q25
		3Q	4Q	FY	1Q	2Q	3Q	
PRODUCTION	New Annualized Premiums¹	\$125.1	\$128.5	\$479.2	\$117.4	\$127.7	\$126.7	1.3%
	Consumer	106.1	108.7	408.0	99.8	104.4	104.3	-1.7%
	Worksite	19.0	19.8	71.2	17.6	23.3	22.4	17.9%
	Annuity Collected Premiums	\$472.5	\$508.3	\$1,943.3	\$433.8	\$536.0	\$514.0	8.8%
	Fee Revenue^{1,2}	\$33.0	\$71.4	\$185.3	\$42.8	\$18.5	\$14.4	n/m
	Consumer	26.2	71.4	163.7	42.8	18.5	14.4	-45.0%
	Worksite	6.8	--	21.6	--	--	--	n/m
DISTRIBUTION	Policyholder and Client Assets	\$18,108	\$18,307	--	\$18,497	\$19,395	\$19,753	9.1%
	Annuity Account Values	13,068	13,271	--	13,415	13,705	13,956	6.8%
	Client Assets in BD and Advisory ¹	5,040	5,036	--	5,082	5,690	5,797	15.0%
	Producing Agent Counts (PAC)¹	4,928	5,016	--	4,967	5,125	5,123	4.0%
INVESTMENTS & CAPITAL	Consumer	4,518	4,612	--	4,566	4,697	4,689	3.8%
	Worksite	410	404	--	401	428	434	5.9%
	Average Book Value of Investments & Cash	\$30,878	\$31,462	--	\$32,039	\$32,712	\$33,451	8.3%
	Average Yield on Allocated Investments	4.91%	4.92%	4.91%	4.88%	4.91%	4.91%	0 bps
	New Money Rate	6.20%	6.11%	--	6.08%	6.16%	6.24%	4 bps
	Book Value per Diluted Share x AOCI³	\$38.10	\$38.81	--	\$38.98	\$39.92	\$41.29	8.4%
	3-year CAGR	6.1%	6.8%	--	7.0%	7.3%	7.0%	--

(dollars in millions)

1 See page 25 for a glossary of terms and definitions.

2 Beginning in 4Q25, Worksite Division fee services revenue will be reported as non-operating due to the previously announced exit of the business.

3 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure.

n/m Result not meaningful following the reclassification of Worksite fee revenue to non-operating results in 4Q25.

CONSUMER DIVISION UPDATE

16th consecutive quarter of sales growth¹; Continued strength in career field agent channel

Operational Highlights

- Career field agent NAP up 13%
- Health NAP up 7%
 - Medicare Supplement NAP up 41%
 - LTC NAP up 2%
- Annuity collected premiums up 9%
 - Account values up 7%
- Record client assets in brokerage and advisory, up 15%
 - Total accounts up 13%

Distribution Highlights

- PAC up 4%; 15th consecutive quarter of growth
 - Strong agent productivity and retention
 - Registered agents up 4%
- Total Medicare policies sold up 20%
- NAP generated from non-TV lead sources represented 71% of total D2C sales

¹ See page 25 for a glossary of terms and definitions.

WORKSITE DIVISION UPDATE

18th consecutive quarter of sales growth¹; 8th consecutive quarter of double-digit growth

Operational Highlights

- Career field agent NAP up 29%
- Life and Health NAP up 18%
 - Life NAP up 59%
 - Hospital Indemnity NAP up 16%
 - Accident NAP up 16%

Distribution Highlights


- Record PAC, up 6%; 17th consecutive quarter of growth
 - Productivity up across all cohorts
- NAP from new clients up 168%

¹ See page 25 for a glossary of terms and definitions.

FINANCIAL HIGHLIGHTS

Operating EPS excluding significant items¹ up 48%; Year-to-date up 45%

Earnings Results



Highlights

- Operating EPS¹ of \$1.90, up 47%
 - Net favorable results from annual actuarial review
- Operating EPS¹ of \$1.42, up 48% excluding significant items
 - Strong sales contributing to growth in insurance product margin and net investment income
 - Improvement in net investment income not allocated led by alternative investment returns
 - Favorable expenses
- Announced 3rd reinsurance transaction with Bermuda affiliate
- \$60 million of share repurchases
 - 4% reduction in weighted average diluted shares outstanding
- Maintained robust total capital position
- TTM operating ROE¹ of 15.4%; 14.1% excluding significant items

Net operating income ¹	\$127.2	\$179.1	\$295.8	\$399.9
Net operating income excluding significant items ¹	\$95.0	\$134.2	\$258.3	\$355.0
Net Income	\$23.1	\$161.1	\$136.4	\$324.7
Weighted average shares outstanding (in millions)	98.6	94.3	100.7	95.1

(dollars in millions, except per share amounts); TTM = trailing twelve months

¹ A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure.

INSURANCE PRODUCT MARGIN

Total margin up 7%, primarily driven by continued sales momentum

Insurance Product Margin Excluding Significant Items¹

	3Q25	4Q25	1Q26	2Q26	3Q26
Annuity	\$56.3	\$56.4	\$58.5	\$60.6	\$67.4
Fixed Indexed Annuities	\$45.9	\$46.4	\$50.2	\$49.2	\$53.4
Fixed Interest Annuities	\$8.5	\$8.2	\$7.3	\$7.8	\$9.2
Other Annuities	\$1.9	\$1.8	\$1.0	\$3.6	\$4.8
Health	\$135.9	\$139.4	\$132.6	\$147.2	\$141.3
Supplemental Health	\$72.3	\$74.1	\$71.2	\$70.1	\$72.8
Medicare Supplement	\$30.4	\$28.6	\$23.1	\$36.5	\$29.9
Long-term Care	\$33.2	\$36.7	\$38.3	\$40.6	\$38.6
Life	\$67.0	\$70.0	\$65.8	\$71.2	\$68.0
Interest Sensitive Life	\$20.7	\$24.8	\$22.8	\$26.4	\$23.0
Traditional Life	\$46.3	\$45.2	\$43.0	\$44.8	\$45.0
Total Margin	\$259.2	\$265.8	\$256.9	\$279.0	\$276.7

Highlights

Annuity margin

- Fixed Indexed Annuities (FIA) – growth in the block and go-forward income pattern change from annual actuarial review
- Other Annuities – favorable reserve releases on closed block policies

Health margin

- Supplemental Health – growth in the block offset by less favorable morbidity
- Medicare Supplement – Higher morbidity, partially offset by growth in the block and implementation of rate increases
- LTC – growth in the block and lower morbidity

Life margin

- ISL – growth in the block and lower mortality
- Traditional Life – higher nondeferrable advertising expense

Annual actuarial review

- Current period net benefit of \$56.3 million, reflecting broad-based favorable experience, partially offset by Medicare Supplement
- Quarterly go-forward income pattern changes
 - FIA +\$3.5mm, Med Supp +\$1mm


(dollars in millions)

¹ Excludes impacts from the annual actuarial review. See the Appendix for a reconciliation to the corresponding GAAP measure and a breakdown of impacts by major product category.

INVESTMENT RESULTS


Total net investment income¹ up 13%; 12th consecutive quarter of growth

Investment Income Allocated to Product Lines




- Average yield on allocated investments of 4.91% in 3Q26, unchanged from 3Q25
- Average net insurance liabilities² up 4.3%

Investment Income Not Allocated to Product Lines



- Favorable net investment income on alternative assets
- Higher FHLB and FABN funding and margins

Total Net Investment Income¹



- New money rate of 6.24% in 3Q26, 15th consecutive quarter over 6%
- Average book value of invested assets up 8.3%
- Earned yield of 5.16% in 3Q26 vs. 4.77% in 3Q25

■ Annuity ■ Health ■ Life ■ Not allocated

(dollars in millions)


¹ Reflects sum of allocated and non-allocated investment income. Refer to pages 15-17 of the financial supplement for more information on the components of net investment income.

² Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.

CAPITAL AND LIQUIDITY OVERVIEW


Robust total capital position

Consolidated Risk Based Capital (RBC) Ratio¹




- Managing RBC Ratio in the range of 360% – 390%
- RBC ratio variability expected in periods of market volatility

Holding Company Liquidity



- Target minimum holding company liquidity of \$150 million
- Liquidity backstopped by \$250 million undrawn revolver
- Staggered debt maturities in 2029 and 2034

Debt to Capital²



- Target leverage of 25% - 28%
- Debt covenant ceiling of 35%
- \$168 million in debt capacity to top of target leverage range
- Debt to capital² excluding \$500 million note that matured May 2025

(dollars in millions)

¹ The ratio of the combined capital of the insurance companies to the minimum amount of capital appropriate to support the overall business operations, as determined based on the methodology developed by the National Association of Insurance Commissioners.

² Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure.

Raising full-year operating EPS guidance 9% at the midpoint



Operating Return on Equity

- 2026 results expected to exceed 2027 target of 12.0%
- Expect to establish new long-term operating ROE targets in February 2027, in line with our normal planning cadence



2026 Operating Earnings

- \$5.05 – \$5.15 operating EPS
- 18.6% – 18.8% expense ratio
- ~20.5% effective tax rate



2026 Free Cash Flow / Excess Capital

- \$220 – \$240 million free cash flow
- 360% – 390% RBC Ratio
- \$150 million minimum holding company liquidity
- 25% – 28% debt to total capital ratio

Guidance excludes significant items

WHY INVEST IN CNO

1

Exclusive middle-market focus and “last-mile” captive distribution create a durable competitive moat

2

Significant demographic tailwinds

3

Sustained growth while improving ROE and modernizing the business

4

Proven investment results built on a foundation of strong asset quality and disciplined management

5

Strong balance sheet and robust free cash flow resilient against market events

6

Track record of execution and delivering on our promises

Questions and Answers

Appendix 1: Quarter in Review

▪ Cash Flow Profile	Slide 16
▪ Broker-Dealer/Registered Investment Advisor	Slide 17
▪ Expense Ratio	Slide 18
▪ Portfolio Composition	Slide 19
▪ New Money Summary	Slide 20
▪ Private Credit	Slide 21
▪ Financial Results Seasonality	Slide 22
▪ Long-Term Care Insurance	Slide 23
▪ Tax Asset Summary	Slide 24
▪ Glossary of Terms and Definitions	Slide 25

CASH FLOW PROFILE

	For the Quarter		Trailing Twelve Months	
	3Q25	3Q26	3Q25	3Q26
Holding Company Cash Flows:				
Net Dividends (Contributions) from/to Subsidiaries	\$ -	\$ -	\$ 69.3	\$ 293.8
Management Fees	31.5	34.5	125.1	128.6
Surplus Debenture Interest	29.4	14.8	77.0	59.0
Earnings on Corporate Investments	3.1	3.0	33.7	16.0
Other	32.6	38.8	25.0	45.5
Holding Company Sources of Cash¹	96.6	91.1	330.1	542.9
Holding Company Expenses and Other	(23.9)	(23.7)	(83.6)	(176.7)
Net Tax Receipts (Payments)	13.0	8.2	22.1	57.7
Interest Payments	(2.1)	(2.1)	(110.0)	(79.8)
Free Cash Flow¹	83.6	73.5	158.6	344.1
Notes Payable Repayment	-	-	(500.0)	-
Share Repurchases	(60.6)	(59.5)	(351.9)	(240.5)
Dividend Payments to Stockholders	(16.4)	(16.5)	(66.4)	(66.6)
Net Change in Holding Company Cash and Investments	6.6	(2.5)	(759.7)	37.0
Cash and Investments, Beginning of Period	187.1	233.2	953.4	193.7
Cash and Investments, End of Period	\$ 193.7	\$ 230.7	\$ 193.7	\$ 230.7

(dollars in millions)

¹ Cash flows exclude acquisitions, dividend payments, stock repurchases, and financing transactions.

BROKER-DEALER/REGISTERED INVESTMENT ADVISOR

Record client assets in brokerage and advisory; Registered agent count up 4%

		2025		2026		
		3Q	4Q	1Q	2Q	3Q
Net New Client Assets in Brokerage and Advisory¹	Brokerage	\$ 74.1	\$ 67.6	\$ 63.1	\$ 75.1	\$ 44.1
	Advisory	124.2	(90.2)	99.2	120.6	90.5
	Total	\$ 198.3	\$ (22.6)	\$ 162.3	\$ 195.7	\$ 134.6
Client Assets in Brokerage and Advisory¹ at end of period	Brokerage	\$ 2,472.4	\$ 2,543.2	\$ 2,521.9	\$ 2,749.7	\$ 2,749.0
	Advisory	2,567.3	2,493.0	2,560.1	2,940.5	3,048.4
	Total	\$ 5,039.7	\$ 5,036.2	\$ 5,082.0	\$ 5,690.2	\$ 5,797.4
Registered Agent Counts^{2,3}	Total	766	781	794	792	795

¹ Client assets include cash and securities in brokerage, broker-dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts.

Bankers Life is the marketing brand of various affiliated companies of CNO Financial Group including, Bankers Life and Casualty Company, Bankers Life Securities, Inc., and Bankers Life Advisory Services, Inc. Non-affiliated insurance products are offered through Bankers Life General Agency, Inc. (dba BL General Insurance Agency, Inc., AK, AL, CA, NV, PA). Agents who are financial advisors are registered with Bankers Life Securities, Inc.

Securities and variable annuity products and services are offered by Bankers Life Securities, Inc. Member FINRA/SIPC, (dba BL Securities, Inc., AL, GA, IA, IL, MI, NV, PA). Advisory products and services are offered by Bankers Life Advisory Services, Inc. SEC Registered Investment Adviser (dba BL Advisory Services, Inc., AL, GA, IA, MT, NV, PA). Home Office: 303 East Wacker Drive, 5th Floor, Chicago, IL 60601.

² Registered agents are dually licensed as insurance agents and financial representatives who can buy and sell securities for clients, and/or investment advisors who can provide ongoing investment advice for clients.

³ Representative counts represent the average of the last 3 months.

(dollars in millions)

EXPENSE RATIO¹

	2025		2026		
	3Q	4Q	1Q	2Q	3Q
Allocated & Non Allocated Expenses	\$ 173.3	\$ 169.5	\$ 179.3	\$ 176.2	\$ 179.8
Allocated & Non Allocated Expenses - YTD	529.5	699.0	179.3	355.5	535.3
Significant Items ²	\$ -	\$ -	\$ -	\$ -	\$ -
Significant Items - YTD ²	-	-	-	-	-
Allocated & Non Allocated Expenses Excluding Significant Items	\$ 173.3	\$ 169.5	\$ 179.3	\$ 176.2	\$ 179.8
Allocated & Non Allocated Expenses Excluding Significant Items - YTD	529.5	699.0	179.3	355.5	535.3
Policy Income and Net Investment Income Allocated to Products	\$ 929.3	\$ 935.9	\$ 946.9	\$ 958.8	\$ 970.8
Policy Income and Net Investment Income Allocated to Products - YTD	2,761.0	3,696.9	946.9	1,905.7	2,876.5
Expense Ratio	18.6%	18.1%	18.9%	18.4%	18.5%
Expense Ratio - YTD	19.2%	18.9%	18.9%	18.7%	18.6%
Rolling Twelve Months Ratio	19.0%	18.9%	18.7%	18.5%	18.5%

(dollars in millions)


1 Expense ratio calculation = expenses allocated to products plus not allocated to products, divided by the sum of insurance policy income and net investment income allocated to products. Results exclude significant items.

2 See pages 27-30 for a reconciliation of the significant items.

PORTFOLIO COMPOSITION

High-quality, liquid portfolio producing solid and consistent results

\$31 Billion of Invested Assets¹



Highlights


- High degree of liquidity: over 57% of portfolio in corporate and government bonds
- Strong credit risk profile
 - Capital efficient: ~97% rated NAIC 1 or 2
 - Portfolio average rating A
 - CRE and private credit portfolios performing as expected

General Approach

- Positioned for stable performance across credit cycles
- Focus on quality - margin against adverse development
- Low impairments through multiple cycles
- Embedded asset liability management
- Opportunistic investments protect/grow book yield and core earnings power
- Growth in AUM leverages increasing book yield, resulting in higher net investment income

¹ Fair Value as of 9/30/2026.

NEW MONEY SUMMARY



3Q26 General Account New Money Purchases


	\$	%	GAAP YTM
IG Corp AAA-A	496.2	29.9%	6.12%
ABS	335.4	20.2%	6.00%
IG Corp BBB	335.4	20.2%	6.05%
Residential Mortgage Loans	153.8	9.3%	6.34%
Municipals	97.7	5.9%	5.82%
CRE Loans	89.6	5.4%	5.37%
Alternatives	58.1	3.5%	11.99%
EM	35.9	2.2%	5.63%
CMBS	29.0	1.8%	5.54%
Rated Notes	20.1	1.2%	6.86%
CLO Debt	5.0	0.3%	5.68%
HY Corp	2.0	0.1%	7.63%
Total	1,658.2	100.0%	0.00%

(dollars in millions)


PRIVATE CREDIT

\$2.3B of exposure diversified across asset managers, structures, vintages; 2,000+ underlying credits


By Asset Class




By Rating¹



By Structure



By Rating Agency



¹ Non-rated (NR) holdings primarily consist of LPs, residuals, and interval funds, all of which are part of our Alternatives allocation but included here because they have private credit exposure.

FINANCIAL RESULTS SEASONALITY

	1Q	2Q	3Q	4Q
Medicare Supplement Margin	Seasonally highest claims and surrenders			
Mortality	Seasonally highest mortality			
D2C Advertising	Traditionally highest advertising	Quarterly trend similar to 2025		Traditionally lowest advertising
Fee Income	~1/3 income	Near breakeven	Near breakeven	~2/3 income
Expenses	Traditionally highest expense ratio			Traditionally lowest expense ratio

LONG-TERM CARE INSURANCE

Highly differentiated; prudently-managed in-force block

New sales focused on short duration products

- Recent growth due to strong sales in LTC Fundamental product
- 99% of new sales for policies with 2 years or less in benefits
- Average benefit period of 13 months for policies sold in 2026

Reserve assumptions informed by historical experience

- No morbidity improvement
- No mortality improvement
- Minimal future rate increases

Favorable economic profile

- Total LTC is just 11% of overall CNO insurance liabilities
- Downside risk significantly reduced after 2018 reinsurance transaction
- Average maximum benefit at issuance is \$168 per day for in-force block

Block highlights

- Less than 22% of policies have inflation benefits
- 2% of policies have lifetime benefits, the median benefit period is ~1 year, and the average non-lifetime benefit period is ~1.4 years
- Average attained age is 75 years

TAX ASSET SUMMARY AS OF SEPTEMBER 30, 2026

\$176 million / \$1.88 per diluted share value of remaining NOLs

Value of NOLs

\$176

NOLs with no
Expiration Date
\$176

Details

- Remaining NOLs are expected to be fully utilized and can generally offset 80% of non-life taxable income and 35% of life taxable income
- Total estimated economic value of tax assets related to our NOLs of approximately \$147 million @ 10% discount rate (\$1.57 on a per diluted share basis)

(dollars in millions)

GLOSSARY OF TERMS AND DEFINITIONS

New Annualized Premiums – Measured as 100% of new Life and Health annualized premiums and 10% of Single Premium Whole Life deposits.

Fee Revenue – Represents fee revenue from the sales of third-party insurance products, fees generated by our broker-dealer and registered investment advisor, and prior to 4Q25, fee revenue earned by the Worksite Division fee services business.

Client Assets in Broker-Dealer (BD) and Advisory – Client assets include cash and securities in brokerage, broker-dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts.

Producing Agent Counts (PAC) – Producing agents represent the monthly average of exclusive agents that have submitted at least one policy in the month.

Sales Growth Measure – Sales growth is measured using 100% of new Life and Health annualized premium, 10% of Single Premium Whole Life deposits, and 6% of Annuity collected premium.

Appendix 2: Financial Exhibits

Non-GAAP Financial Measures

Slides 27 - 42

3Q26 SIGNIFICANT ITEMS

The table below summarizes the financial impact of significant items on our 3Q26 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.

	Three months ended September 30, 2026		
	Actual results	Significant items	Excluding significant items
Insurance product margin			
Annuity	\$ 87.9	\$ (20.5) ^(a)	\$ 67.4
Health	149.1	(7.8) ^(a)	141.3
Life	96.0	(28.0) ^(a)	68.0
Total insurance product margin	333.0	(56.3)	276.7
Allocated expenses	(161.0)	-	(161.0)
Income from insurance products	172.0	(56.3)	115.7
Fee income	(1.1)	-	(1.1)
Investment income not allocated to product lines	68.1	-	68.1
Expenses not allocated to product lines	(18.8)	-	(18.8)
Operating earnings before taxes	220.2	(56.3)	163.9
Income tax (expense) benefit on operating income	(41.1)	11.4	(29.7)
Net operating income (b)	<u>\$ 179.1</u>	<u>\$ (44.9)</u>	<u>\$ 134.2</u>
Net operating income per diluted share (b)	<u>\$ 1.90</u>	<u>\$ (0.48)</u>	<u>\$ 1.42</u>

(dollars in millions, except per-share amounts)

(a) Comprised of \$56.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

(b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure.

2025 SIGNIFICANT ITEMS

The table below summarizes the financial impact of significant items on our 2025 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.

	Year ended December 31, 2025		
	Actual Results	Significant Items	Excluding significant items
Insurance product margin			
Annuity	\$ 238.6	\$ (16.6) ^(a)	\$ 222.0
Health	556.6	(21.1) ^(a)	535.5
Life	272.4	(10.4) ^(a)	262.0
Total insurance product margin	1,067.6	(48.1)	1,019.5
Allocated expenses	(611.3)	-	(611.3)
Income from insurance products	456.3	(48.1)	408.2
Fee income	15.2	-	15.2
Investment income not allocated to product lines	169.4	-	169.4
Expenses not allocated to product lines	(87.7)	-	(87.7)
Operating earnings before taxes	553.2	(48.1)	505.1
Income tax (expense) benefit on operating income	(114.0)	10.6	(103.4)
Net operating income (b)	<u>\$ 439.2</u>	<u>\$ (37.5)</u>	<u>\$ 401.7</u>
Net operating income per diluted share (b)	<u>\$ 4.40</u>	<u>\$ (0.38)</u>	<u>\$ 4.02</u>

(dollars in millions, except per-share amounts)

(a) Comprised of \$41.3 million of the net favorable impact arising from our comprehensive annual actuarial review during 3Q25 and \$6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves, during 1Q25.

(b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure.

3Q25 SIGNIFICANT ITEMS

The table below summarizes the financial impact of significant items on our 3Q25 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.

	Three months ended September 30, 2025		
	Actual results	Significant items	Excluding significant items
Insurance product margin			
Annuity	\$ 72.9	\$ (16.6) ^(a)	\$ 56.3
Health	157.0	(21.1) ^(a)	135.9
Life	70.6	(3.6) ^(a)	67.0
Total insurance product margin	300.5	(41.3)	259.2
Allocated expenses	(151.0)	-	(151.0)
Income from insurance products	149.5	(41.3)	108.2
Fee income	(3.9)	-	(3.9)
Investment income not allocated to product lines	39.5	-	39.5
Expenses not allocated to product lines	(22.3)	-	(22.3)
Operating earnings before taxes	162.8	(41.3)	121.5
Income tax (expense) benefit on operating income	(35.6)	9.1	(26.5)
Net operating income (b)	<u>\$ 127.2</u>	<u>\$ (32.2)</u>	<u>\$ 95.0</u>
Net operating income per diluted share (b)	<u>\$ 1.29</u>	<u>\$ (0.33)</u>	<u>\$ 0.96</u>

(dollars in millions, except per-share amounts)

(a) Comprised of \$41.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

(b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure.

1Q25 SIGNIFICANT ITEMS

The table below summarizes the financial impact of significant items on our 1Q25 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results.

	Three months ended March 31, 2025		
	Actual results	Significant items	Excluding significant items
Insurance product margin			
Annuity	\$ 54.5	\$ -	\$ 54.5
Health	126.2	-	126.2
Life	68.2	(6.8) ^(a)	61.4
Total insurance product margin	248.9	(6.8)	242.1
Allocated expenses	(161.2)	-	(161.2)
Income from insurance products	87.7	(6.8)	80.9
Fee income	(0.8)	-	(0.8)
Investment income not allocated to product lines	38.0	-	38.0
Expenses not allocated to product lines	(20.3)	-	(20.3)
Operating earnings before taxes	104.6	(6.8)	97.8
Income tax (expense) benefit on operating income	(23.5)	1.5	(22.0)
Net operating income (b)	<u>\$ 81.1</u>	<u>\$ (5.3)</u>	<u>\$ 75.8</u>
Net operating income per diluted share (b)	<u>\$ 0.79</u>	<u>\$ (0.05)</u>	<u>\$ 0.74</u>

(dollars in millions, except per-share amounts)

(a) Comprised of \$6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves.

(b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure.

QUARTERLY EARNINGS

	3Q25	4Q25	1Q26	2Q26	3Q26
Insurance product margin					
Annuity	\$ 72.9	\$ 56.4	\$ 58.5	\$ 60.6	\$ 87.9
Health	157.0	139.4	132.6	147.2	149.1
Life	70.6	70.0	65.8	71.2	96.0
Total insurance product margin	300.5	265.8	256.9	279.0	333.0
Allocated expenses	(151.0)	(149.7)	(159.9)	(152.9)	(161.0)
Income from insurance products	149.5	116.1	97.0	126.1	172.0
Fee income	(3.9)	19.1	10.6	(1.2)	(1.1)
Investment income not allocated to product lines	39.5	58.1	41.7	49.4	68.1
Expenses not allocated to product lines	(22.3)	(19.8)	(19.4)	(23.3)	(18.8)
Operating earnings before taxes	162.8	173.5	129.9	151.0	220.2
Income tax expense on operating income	(35.6)	(30.1)	(28.6)	(31.5)	(41.1)
Net operating income*	127.2	143.4	101.3	119.5	179.1
Net realized investment gains (losses) from disposals, impairments and change in allowance for credit losses	(8.8)	(25.2)	(15.2)	(13.6)	(48.3)
Net change in market value of investments recognized in earnings	5.8	(1.3)	(7.5)	(1.1)	(16.4)
Fair value changes related to agent deferred compensation plan	-	(1.7)	-	-	10.0
Changes in fair value of embedded derivative liabilities and market risk benefits	(18.1)	(1.5)	(42.4)	34.6	69.7
Expenses related to TechMod initiative	(7.2)	(9.9)	(13.7)	(9.7)	(10.1)
Goodwill and other asset impairment	(96.7)	(5.2)	-	-	-
Net loss related to divested business	-	(17.3)	(1.9)	(1.1)	-
Other	(1.6)	-	(0.8)	(0.4)	1.3
Non-operating income (loss) before taxes	(126.6)	(62.1)	(81.5)	8.7	6.2
Income tax (expense) benefit on non-operating income (loss)	22.5	11.6	17.9	(2.3)	(2.1)
Valuation allowance for deferred tax assets	-	-	-	-	(22.1)
Net non-operating income (loss)	(104.1)	(50.5)	(63.6)	6.4	(18.0)
Net income	\$ 23.1	\$ 92.9	\$ 37.7	\$ 125.9	\$ 161.1

*Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 33.

(dollars in millions)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

The following provides additional information regarding certain non-GAAP measures used in this presentation. A non-GAAP measure is a numerical measure of a company's performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. While management believes these measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered as substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the "Investors – SEC Filings" section of CNO's website, www.CNOinc.com.

Operating earnings measures

Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 33.

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

A reconciliation of net income applicable to common stock to net operating income (and related per-share amounts) is as follows:

	3Q25	4Q25	1Q26	2Q26	3Q26
Net income applicable to common stock	\$ 23.1	\$ 92.9	\$ 37.7	\$ 125.9	\$ 161.1
Non-operating items:					
Net realized investment (gains) losses from sales and impairments	8.8	25.2	15.2	13.6	48.3
Net change in market value of investments recognized in earnings	(5.8)	1.3	7.5	1.1	16.4
Fair value changes related to the agent deferred compensation plan	-	1.7	-	-	(10.0)
Changes in fair value of embedded derivative liabilities and market risk benefits	18.1	1.5	42.4	(34.6)	(69.7)
Expenses related to TechMod initiative	7.2	9.9	13.7	9.7	10.1
Goodwill and other asset impairment	96.7	5.2	-	-	-
Net loss related to divested business	-	17.3	1.9	1.1	-
Other	1.6	-	0.8	0.4	(1.3)
Non-operating (income) loss before taxes	126.6	62.1	81.5	(8.7)	(6.2)
Income tax expense (benefit) on non-operating income	(22.5)	(11.6)	(17.9)	2.3	2.1
Valuation allowance for deferred tax assets	-	-	-	-	22.1
Net non-operating (income) loss	104.1	50.5	63.6	(6.4)	18.0
Net operating income (a non-GAAP financial measure)	\$ 127.2	\$ 143.4	\$ 101.3	\$ 119.5	\$ 179.1
Per diluted share:					
Net income	\$ 0.24	\$ 0.95	\$ 0.39	\$ 1.33	\$ 1.71
Net realized investment (gains) losses from sales and impairments (net of taxes)	0.07	0.22	0.12	0.11	0.41
Net change in market value of investments recognized in earnings (net of taxes)	(0.05)	0.01	0.06	0.01	0.14
Changes in fair value of embedded derivative liabilities and market risk benefits (net of taxes)	0.14	0.02	0.34	(0.28)	(0.59)
Fair value changes related to the agent deferred compensation plan (net of taxes)	-	0.01	-	-	(0.08)
Expenses related to TechMod initiative	0.06	0.08	0.11	0.08	0.09
Goodwill and other asset impairment	0.82	0.04	-	-	-
Net loss related to divested business	-	0.14	0.02	0.01	-
Valuation allowance for deferred tax assets	-	-	-	-	0.23
Other	0.01	-	0.01	-	(0.01)
Net operating income (a non-GAAP financial measure)	\$ 1.29	\$ 1.47	\$ 1.05	\$ 1.26	\$ 1.90

(dollars in millions, except per-share amounts)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

A reconciliation of operating income and shares used to calculate basic and diluted operating earnings per share is as follows:

	<u>3Q25</u>	<u>4Q25</u>	<u>1Q26</u>	<u>2Q26</u>	<u>3Q26</u>
Net operating income	<u>\$ 127.2</u>	<u>\$ 143.4</u>	<u>\$ 101.3</u>	<u>\$ 119.5</u>	<u>\$ 179.1</u>
Weighted average shares outstanding for basic earnings per share	96,603	95,136	94,078	93,194	92,195
Effect of dilutive securities on weighted average shares:					
Employee benefit plans	1,951	2,142	2,061	1,758	2,059
Weighted average shares outstanding for diluted earnings per share	98,553	97,278	96,139	94,952	94,253
Net operating income per diluted share	<u>\$ 1.29</u>	<u>\$ 1.47</u>	<u>\$ 1.05</u>	<u>\$ 1.26</u>	<u>\$ 1.90</u>

(dollars in millions, except per-share amounts, and shares in thousands)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

Book value per diluted share

Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.

A reconciliation from book value per share to book value per diluted share, excluding accumulated other comprehensive income (loss) is as follows:

	<u>3Q25</u>	<u>4Q25</u>	<u>1Q26</u>	<u>2Q26</u>	<u>3Q26</u>
Total shareholders' equity	\$ 2,611.0	\$ 2,638.2	\$ 2,498.4	\$ 2,591.6	\$ 2,323.7
Shares outstanding for the period	<u>95,840,989</u>	<u>94,484,339</u>	<u>93,795,306</u>	<u>92,696,990</u>	<u>91,705,509</u>
Book value per share	<u>\$ 27.24</u>	<u>\$ 27.92</u>	<u>\$ 26.64</u>	<u>\$ 27.96</u>	<u>\$ 25.34</u>
Total shareholders' equity	\$ 2,611.0	\$ 2,638.2	\$ 2,498.4	\$ 2,591.6	\$ 2,323.7
Accumulated other comprehensive loss	(1,118.9)	(1,115.0)	(1,217.6)	(1,182.8)	(1,545.8)
Adjusted shareholders' equity excluding AOCI	<u>\$ 3,729.9</u>	<u>\$ 3,753.2</u>	<u>\$ 3,716.0</u>	<u>\$ 3,774.4</u>	<u>\$ 3,869.5</u>
Shares outstanding for the period	95,840,989	94,484,339	93,795,306	92,696,990	91,705,509
Dilutive common stock equivalents related to:					
Stock options, restricted stock and performance units	2,061,774	2,229,874	1,528,160	1,854,426	2,015,117
Diluted shares outstanding	<u>97,902,763</u>	<u>96,714,213</u>	<u>95,323,466</u>	<u>94,551,416</u>	<u>93,720,626</u>
Book value per diluted share excluding AOCI (a non-GAAP measure)	<u>\$ 38.10</u>	<u>\$ 38.81</u>	<u>\$ 38.98</u>	<u>\$ 39.92</u>	<u>\$ 41.29</u>

(dollars in millions, except share and per-share amounts)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

Operating return measures

Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines.

Management also believes that an operating return, excluding significant items, is important as the impact of these items enhances the understanding of our operating results.

This non-GAAP financial measure also differs from return on equity because accumulated other comprehensive income (loss) has been excluded from the value of equity used to determine this ratio. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management.

In addition, our equity includes the value of significant net operating loss carryforwards (included in income tax assets on our consolidated balance sheet). In accordance with GAAP, these assets are not discounted and accordingly will not provide a return to shareholders (until after it is realized as a reduction to taxes that would otherwise be paid). Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns and the comparability of these measures from period-to-period. Operating return measures are used in measuring the performance of our business units and are used as a basis for incentive compensation.

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

The calculations of: (i) Operating return on equity (a non-GAAP financial measure); (ii) Operating return, excluding significant items, on equity (a non-GAAP financial measure); and (iii) return on equity are as follows:

	Twelve Months Ended				
	3Q25	4Q25	1Q26	2Q26	3Q26
Net operating income	\$ 433.8	\$ 439.2	\$ 459.4	\$ 491.4	\$ 543.3
Net operating income, excluding significant items	\$ 399.4	\$ 401.7	\$ 427.2	\$ 459.2	\$ 498.4
Net income	\$ 319.3	\$ 229.3	\$ 245.5	\$ 279.6	\$ 417.6
Average common equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure)	\$ 3,580.0	\$ 3,536.7	\$ 3,494.5	\$ 3,495.4	\$ 3,522.7
Average common shareholders' equity	\$ 2,560.6	\$ 2,566.4	\$ 2,574.7	\$ 2,576.2	\$ 2,548.9
Operating return on equity (a non-GAAP financial measure)	12.1%	12.4%	13.1%	14.1%	15.4%
Operating return on equity, excluding significant items (a non-GAAP financial measure)	11.2%	11.4%	12.2%	13.1%	14.1%
Return on equity	12.5%	8.9%	9.5%	10.9%	16.4%

Trailing four quarters average equity is calculated using the following formula (P = Period) – $((P1+P2)/2 + (P2+P3)/2 + (P3+P4)/2 + (P4+P5)/2)/4$
[e.g. – the formula for calculating 3Q26 average equity would be the following – $((3Q25+4Q25)/2 + (4Q25+1Q26)/2 + (1Q26+2Q26)/2 + (2Q26+3Q26)/2)/4$]

(dollars in millions)
(Continued on next page)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

The following summarizes: (i) operating earnings; (ii) significant items; (iii) operating earnings, excluding significant items; and (iv) net income (loss):

	Net operating income	Significant items (a)	Net operating income, excluding significant items	Net operating income, excluding significant items - trailing four quarters	Net income (loss)	Net income - trailing four quarters
4Q24	\$ 138.0	\$ 3.1	\$ 141.1	\$ 410.5	\$ 182.9	\$ 420.8
1Q25	81.1	(5.3)	75.8	428.8	21.5	330.0
2Q25	87.5	-	87.5	401.7	91.8	305.5
3Q25	127.2	(32.2)	95.0	399.4	23.1	319.3
4Q25	143.4	-	143.4	401.7	92.9	229.3
1Q26	101.3	-	101.3	427.2	37.7	245.5
2Q26	119.5	-	119.5	459.2	125.9	279.6
3Q26	179.1	(44.9)	134.2	498.4	161.1	417.6

(dollars in millions)

(a) The significant items have been discussed in either the current or prior press releases.

(Continued on next page)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows:

	Twelve Months Ended				
	3Q25	4Q25	1Q26	2Q26	3Q26
Pre-tax operating earnings (a non-GAAP financial measure)	\$553.6	\$553.2	\$578.5	\$617.2	\$674.6
Income tax expense	(119.8)	(114.0)	(119.1)	(125.8)	(131.3)
Operating return	433.8	439.2	459.4	491.4	543.3
Non-operating items:					
Net realized investment losses from sales and impairments	(78.9)	(69.0)	(71.0)	(62.8)	(102.3)
Net change in market value of investments recognized in earnings	9.0	14.3	0.4	(4.1)	(26.3)
Changes in fair value of embedded derivative liabilities and market risk benefits	30.1	(64.0)	(36.8)	(27.4)	60.4
Fair value changes and amendment related to the agent deferred compensation plan	6.6	(1.7)	(1.7)	(1.7)	8.3
Expenses related to TechMod initiative	(10.4)	(20.3)	(34.0)	(40.5)	(43.4)
Goodwill and other asset impairment	(96.7)	(101.9)	(101.9)	(101.9)	(5.2)
Net loss related to divested business	-	(17.3)	(19.2)	(20.3)	(20.3)
Other	0.8	0.1	(0.3)	(2.8)	0.1
Non-operating income (loss) before taxes	(139.5)	(259.8)	(264.5)	(261.5)	(128.7)
Income tax (expense) benefit on non-operating income (loss)	25.0	49.9	50.6	49.7	25.1
Valuation allowance for deferred tax assets	-	-	-	-	(22.1)
Net non-operating income (loss)	(114.5)	(209.9)	(213.9)	(211.8)	(125.7)
Net income	<u>\$319.3</u>	<u>\$229.3</u>	<u>\$245.5</u>	<u>\$279.6</u>	<u>\$417.6</u>

(dollars in millions)

(Continued on next page)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows:

	1Q24	2Q24	3Q24	4Q24
Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure)	\$ 3,536.8	\$ 3,596.7	\$ 3,529.9	\$ 3,810.0
Net operating loss carryforwards	311.2	296.5	273.9	76.6
Accumulated other comprehensive loss	(1,480.3)	(1,464.3)	(1,116.0)	(1,371.4)
Common shareholders' equity	<u>\$ 2,367.7</u>	<u>\$ 2,428.9</u>	<u>\$ 2,687.8</u>	<u>\$ 2,515.2</u>
	1Q25	2Q25	3Q25	4Q25
Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure)	\$ 3,498.9	\$ 3,504.3	\$ 3,483.6	\$ 3,510.2
Net operating loss carryforwards	295.3	271.1	246.3	243.0
Accumulated other comprehensive loss	(1,239.1)	(1,252.7)	(1,118.9)	(1,115.0)
Common shareholders' equity	<u>\$ 2,555.1</u>	<u>\$ 2,522.7</u>	<u>\$ 2,611.0</u>	<u>\$ 2,638.2</u>
	1Q26	2Q26	3Q26	
Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure)	\$ 3,461.2	\$ 3,548.5	\$ 3,658.3	
Net operating loss carryforwards	254.8	225.9	211.2	
Accumulated other comprehensive loss	(1,217.6)	(1,182.8)	(1,545.8)	
Common shareholders' equity	<u>\$ 2,498.4</u>	<u>\$ 2,591.6</u>	<u>\$ 2,323.7</u>	

(dollars in millions)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders' equity, is as follows:

		Trailing Four Quarter Average			
	3Q25	4Q25	1Q26	2Q26	3Q26
Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure)	\$ 3,580.0	\$ 3,536.7	\$ 3,494.5	\$ 3,495.4	\$ 3,522.7
Net operating loss carryforwards	225.8	243.1	258.9	248.1	238.1
Accumulated other comprehensive loss	(1,245.2)	(1,213.4)	(1,178.7)	(1,167.3)	(1,211.9)
Common shareholders' equity	<u>\$ 2,560.6</u>	<u>\$ 2,566.4</u>	<u>\$ 2,574.7</u>	<u>\$ 2,576.2</u>	<u>\$ 2,548.9</u>

(dollars in millions)

INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

Debt to capital ratio, excluding accumulated other comprehensive income (loss)

The debt to capital ratio, excluding accumulated other comprehensive income (loss), differs from the debt to capital ratio because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. A reconciliation of these ratios is as follows:

	2024	2025	1Q26	2Q26	3Q26
Corporate notes payable	\$ 1,833.5	\$ 1,335.6	\$ 1,336.0	\$ 1,336.3	\$ 1,336.7
Total shareholders' equity	2,515.2	2,638.2	2,498.4	2,591.6	2,323.7
Total capital	\$ 4,348.7	\$ 3,973.8	\$ 3,834.4	\$ 3,927.9	\$ 3,660.4
Corporate debt to capital	42.2%	33.6%	34.8%	34.0%	36.5%
Corporate notes payable	\$ 1,833.5	\$ 1,335.6	\$ 1,336.0	\$ 1,336.3	\$ 1,336.7
Total shareholders' equity	2,515.2	2,638.2	2,498.4	2,591.6	2,323.7
Less accumulated other comprehensive (income) loss	1,371.4	1,115.0	1,217.6	1,182.8	1,545.8
Total capital	\$ 5,720.1	\$ 5,088.8	\$ 5,052.0	\$ 5,110.7	\$ 5,206.2
Debt to total capital ratio, excluding AOCI (a non-GAAP financial measure)	32.1%	26.2%	26.4%	26.1%	25.7%
Corporate notes payable	\$1,833.5				
Assumed repayment of 2025 notes, net of unamortized debt issuance costs	(499.5)				
Adjusted corporate notes payable	\$1,334.0				
Total shareholders' equity	\$2,515.2				
Less accumulated other comprehensive loss	1,371.4				
Loss on assumed extinguishment of debt	(0.4)				
Adjusted shareholders' equity	\$3,886.2				
Adjusted total capital	\$5,220.2				
Debt to total capital ratio, excluding AOCI, as adjusted for the assumed repayment of the 2025 Notes (a non-GAAP financial measure)	25.6%				

(dollars in millions)